Indoline compounds as aldosterone synthase inhibitors

US9745282B2 · kind B2 · utility

Assignees

• Merck Sharp & Dohme LLC · US
• ElexoPharm GmbH · DE

Inventors

• Amjad Ali · Freehold, US
• Michael Man-Chu Lo · Rahway, US
• Edward Metzger · Edison, US
• Lina Yin · Riegelsberg, DE
• Rolf Hartmann · Saarburg, DE
• Qingzhong Hu · Riegelsberg, DE
• Ralf Heim · Riegelsberg, DE
• Christina Zimmer · Völklingen, DE

Key dates

• Filing date: Jun 30, 2016
• Grant date: Aug 29, 2017
• Expiry date: Jun 30, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D409/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to indoline compounds of the structural formula:or their pharmaceutically acceptable salts, wherein the variables are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.